

Special Issue

New Trends in Vaccine Characterization, Formulations, and Development

Message from the Guest Editor

Over the last few decades, several platforms have been used for vaccine development, formulation, and delivery. Each platform has its own unique advantages over other platforms. This has led to the availability of different types of vaccines ranging from conventional attenuated or killed whole pathogen to subunit vaccines and, nucleic acid-based vaccines such as mRNA-based vaccines. Even though modern vaccines are proven to be safe and effective, they still suffer from numerous limitations such as poor thermostability, short shelf life at room temperature, and the requirement for specialized needles and syringes. To overcome these issues, new formulations and modes of vaccine delivery are currently under investigation. We would like to encourage submissions on recent advances made in vaccine characterization, formulation, and development, for which original research articles, reviews, communications, case reports, and clinical trials mentioning technological improvements in the field of vaccines are welcome. Papers describing novel formulations, the development of new platforms for vaccine delivery, identification of novel adjuvants, and novel modes of delivery are also welcome.

Guest Editor

Dr. Ravinder Kumar

Department of Biological Sciences, Rensselaer Polytechnic Institute,
Troy, NY 12180, USA

Deadline for manuscript submissions

31 August 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/128560

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).